[Skip to Navigation]
Views 5,297
Citations 0
News From the Food and Drug Administration
March 20, 2018

New Treatment Option for Pneumonia

JAMA. 2018;319(11):1086. doi:10.1001/jama.2018.1812

The FDA has approved a third indication for a fixed-dose combination of ceftazidime and avibactam to treat adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

The newest indication is for HABP/VABP caused by susceptible gram-negative bacteria including Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Pseudomonas aeruginosa, and Haemophilus influenzae.